In the Clinic

Our lead investigational drug, OP-1250, is a novel oral compound developed to completely antagonize the estrogen receptor (ER) and block the ER-mediated cancer cell growth and proliferation signal.

OP-1250 Pipeline

Target Patient Population

Discovery

Nonclinical

Phase I

Phase II

Phase III

Clinical
Collaboration

Metastatic Breast Cancer

ER+, HER2- MBC
(with and without CNS metastases)

ER+, HER2- MBC
(combination with palbociclib)

ER+, HER2- MBC
(combination with ribociclib)

ER+, HER2- MBC with PIK3CA mutated
(combination with alpelisib)

ER+ with ESR1 mutation(1)

HER2+ Metastatic Breast Cancer with CNS METS

ER+, HER2+ MBC with CNS metastases

Gynecology — Oncology

Endometrial Cancer(1)

Gynecologic malignancies

Discovery Pipeline

Target Patient Population

Discovery

Nonclinical

Phase I

Phase II

Phase III

Clinical
Collaboration

Breast Cancer target

Undisclosed Oncology target

Clinical Trials

OP-1250 is currently in development as a treatment for estrogen receptor-positive, HER2-negative metastatic breast cancer (ER+/HER2- MBC), in both monotherapy and combination settings.

Learn more about our culture.